Nomura Holdings Inc. Has $5.58 Million Position in Omeros Corporation $OMER

Key Points

• Nomura Holdings Inc. reduced its stake in Omeros Corporation by 9.1%, now holding 1.16% of the company, valued at approximately $5.58 million.
• Omeros Corporation reported a quarterly earnings beat, with an earnings per share of (0.53), surpassing analysts' expectations of (0.55), along with revenue of $28.60 million.
• Analysts have mixed ratings on Omeros stock, with a consensus rating of "Moderate Buy" and an average target price of $18.00.

Nomura Holdings Inc. lessened its holdings in Omeros Corporation (NASDAQ:OMER - Free Report) by 9.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 679,020 shares of the biopharmaceutical company's stock after selling 68,261 shares during the quarter. Nomura Holdings Inc. owned approximately 1.16% of Omeros worth $5,582,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in OMER. Raymond James Financial Inc. bought a new position in Omeros in the 4th quarter valued at approximately $124,000. Barclays PLC raised its holdings in Omeros by 9.6% in the 4th quarter. Barclays PLC now owns 103,726 shares of the biopharmaceutical company's stock valued at $1,025,000 after buying an additional 9,086 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 1,972 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Omeros by 12.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock valued at $392,000 after buying an additional 4,401 shares during the last quarter. Finally, Comerica Bank raised its holdings in Omeros by 16.7% in the 4th quarter. Comerica Bank now owns 35,000 shares of the biopharmaceutical company's stock valued at $346,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 48.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. D. Boral Capital restated a "buy" rating and set a $36.00 price target on shares of Omeros in a report on Wednesday. Needham & Company LLC restated a "hold" rating on shares of Omeros in a report on Friday, August 15th. Finally, HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Omeros in a report on Friday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Omeros presently has an average rating of "Moderate Buy" and an average target price of $18.00.

Omeros Price Performance

Shares of NASDAQ:OMER traded down $0.01 during mid-day trading on Friday, hitting $4.17. The company had a trading volume of 553,942 shares, compared to its average volume of 968,527. The firm has a fifty day moving average price of $3.85 and a 200 day moving average price of $5.31. The company has a market capitalization of $283.81 million, a PE ratio of -1.98 and a beta of 2.37. Omeros Corporation has a one year low of $2.95 and a one year high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to the consensus estimate of $0.31 million. Research analysts expect that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.